


Amendments to the Claims:

Please amend the claims as set forth below.


Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)
2. (Currently Amended) ~~Compound as claimed in claim 1~~ Polyazamacrocyclic compounds for radiometal labeling comprising an N_n system, wherein n is 4 having the general formula:



3. (Currently Amended) ~~Compound as claimed in claim 1~~ claim 2, which wherein the compound is 1- (1-carboxy-3-carbotertbutoxypropyl)- 4,7,10 (carbotertbutoxymethyl)-1,4,7,10-tetraazacyclododecane (DOTAGA (tBu) 4).
4. (Withdrawn) Chelating compounds for labeling bioactive molecules with a radiometal, having the general formula:




in which:

both Y groups may be positioned either trans as shown or cis;


A is an effector molecule, such as a peptide, in particular octreotide, CCK, substance P, gastrin, a protein, in particular an antibody or enzyme, sugars or radiosensitizing agents, like doxorubicin;

R is a hydrogen, a C₁-C₃ alkyl or a alcohol;

X is a spacer, in particular (CH₂)_n-X', in which n is 1-10 and X' is COOH, NH₂, SH, OH or O-halogen, in which halogen is in particular Br, I or Cl or a molecule of the formula



or of the formula



Y is COO⁻, CH₂CONH₂, CH₂CH₂OH, optionally complexed with a radiometal.

5. (Withdrawn) Compounds as claimed in claim 4, wherein R is hydrogen, n is 1, X' is COOH, and Y is COO⁻.

6. (Withdrawn) Compound as claimed in claim 5, wherein R is hydrogen, n is 1, X' is

COOH, Y is COO⁻ and A is octreotide or octreotate.

7. (Withdrawn) Compound as claimed in claim 4, wherein R is COOH, n is 1, X' is COOH, and Y is COO⁻.

8. (Withdrawn) Compound as claimed in claim 7, wherein R is COOH, n is 1, X' is COOH, Y is COO⁻ and A is octreotide or octreotate.

9. (Withdrawn) Compounds as claimed in claim 4, selected from the group consisting of DOTAtyr³octreotide, DOTAtyr³octreotate, DOTA3tyr³octreotide, DOTA3tyr³octreotate, DOTAt3tyr³octreotide, and DOTAta.13tyr³octreotate.

10. (Cancelled)

11. (Currently Amended) Method for preparing radiometal labeled bioactive molecules, comprising:

a) synthesizing ~~compounds as claimed in claim 1~~

polyazamacrocyclic compounds for radiometal labeling comprising a N_n system, wherein n is 4, 5 or 6, with varying ring size, and wherein at least one of the N atoms is substituted with a free carboxylate group for coupling to an amino function in a bioactive molecule, wherein

all N atoms carry a protected side chain and have

~~having protected side chains on the N atoms and~~ a free carboxylate group;

b) coupling a the bioactive molecule to the free carboxylate group;

c) deprotecting the protected side chains; and

d) labeling a chelator structure thus obtained with a desired radiometal.

12.-14. (Cancelled)

15. (Withdrawn) Method for diagnosing a disease comprising:
labeling the chelating compound of claim 4 with a radiometal to produce a labeled chelating compound; and
diagnosing a disease with said labeled chelating compound.
16. (Withdrawn) A diagnostic or therapeutic composition comprising the chelating compound of claim 4.
17. (Withdrawn) A method for preparing the diagnostic or therapeutic composition of claim 16 comprising
providing said chelating compound; and
reacting said chelating compound with a radiometal.
18. (Withdrawn) The method of claim 17, wherein said radiometal is ^{90}Y .
19. (New) Method for preparing radiometal labeled bioactive molecules, comprising:
a) synthesizing compounds as claimed in claim 2
having protected side chains on the N atoms and a free carboxylate group;
b) coupling a bioactive molecule to the free carboxylate group;
c) deprotecting the protected side chains; and
d) labeling a chelator structure thus obtained with a desired radiometal.